Sanofi Genzyme announced a collaboration with the Johns Hopkins School of Medicine aimed at developing new drugs for progressive multiple sclerosis.
“While there are currently no approved treatments for progressive forms of MS, the research landscape is evolving to where we are learning more about the underlying biology of disease progression,” said Michael Panzara, head of MS, Neurology and Ophthalmology global development at Sanofi Genzyme. “Collaborations like this are important to advancing interventional strategies that slow relentless progression in MS.”
The Johns Hopkins Multiple Sclerosis Center, one of the largest clinical and research MS centers, brings expertise and novel research approaches that complement Sanofi Genzyme’s MS research priorities.
Are you hopeful about this collaboration?
Image found at www.mssociety.org.uk.